News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Pharm Country
Depomed, Inc. Recalls 52 Lots of Diabetes Drug, Glumetza
June 17, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Drug developer Depomed Inc (DEPO.O) said it will recall 52 lots of its diabetes drug Glumetza due to the presence of traces of a certain chemical in the tablet's 500 mg bottle.
Twitter
LinkedIn
Facebook
Email
Print
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
·
3 min read
·
Greg Slabodkin
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
·
2 min read
·
Tyler Patchen
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
·
2 min read
·
Tyler Patchen
